# Gilead Sciences, Inc. – Consensus ‘buy’ rating and 8.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc-consensus-buy-rating-and-8-8-upside-potential-3/4121184557
- Published: 2025-01-22T13:42:14+00:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** which can be found using ticker (GILD) have now 26 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between $125.00 and $73.00 suggesting an average
Analsyt target price of $99.96. Given that the stocks previous close was at $91.84
and the analysts are correct then we can expect a percentage increase in value of
8.8%. It’s also worth noting that there is a 50 day moving average of $91.98 while
the 200 day moving average is $78.64. The market cap for the company is 115.85B.
The price for the stock stands currently at: $92.96 USD

 The potential market cap would be $126,094,435,120 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 1032.89, revenue per share of $22.70
and a 11.96% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on:
